Onco Actu du 25 juin 2018

	3.2 Prévention - Obésité
Obesity epidemic demands more action and investment to protect children [The Guardian] As Theresa May announces strategy such as ban on energy drink sales to children, analysis shows government must go further.
	4.2 Dép., diag. & prono. - Génome
Real-time DNA sequencing in advanced pancreatic cancer can guide precision medicine treatment [Dana-Farber Cancer Institute] Published in Cancer Discovery, the study found that about one-third of 71 patients with metastatic pancreatic cancer had a change in their clinical care because of their genomic data, including the recommendation for some patients that family members consider genetic testing due to a potential inherited predisposition to pancreatic cancer.
	5. Traitements
Robotic surgery is no better than traditional surgery, bladder cancer study finds [Washington Post] Dipen J. Parekh, lead author on the study, said the findings point to the need for rigorous study of surgical innovations like robotic surgery before they receive widespread adoption.
	5.10 Traitements - Essais
Return of Research Results to Study Participants [JAMA] The time to chart and test paths to return health results is now, and this work will be accelerated by greater engagement with researchers and patients and rigorous testing of emerging models for return of results.
	5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
IPO bonanza continues with $150M listing for CAR-T player Autolus [FierceBiotech] Autolus’ lead project is a CAR-T in a phase 1 trial in pediatric relapsed or refractory acute lymphocytic leukemia (ALL) targeting CD19—the same target as already-approved CAR-Ts from Novartis and Gilead/Kite—and it’s also planning early-stage trials for therapies targeting CD19/CD22 and BCMA in lymphomas and multiple myeloma, respectively.
	5.12.4 Immunothérapies - Essais
Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy [Roche] Data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).
Study preserves hopes for Roche's Tecentriq in lung cancer [Reuters] “These are the first positive Phase III survival results for any immunotherapy-based combination in the initial treatment of extensive-stage small cell lung cancer,” Horning said.
	5.12.5 Immunothérapies - Pharma
FDA accepts Bristol-Myers' Opdivo-Yervoy app in lung cancer, but without a speedy review [FiercePharma] In the meantime, while BMS waits for its shot at the lucrative front-line market, Merck will be using Keytruda’s chemo combo showing to further extend the drug’s lead in that space.
Bristol-Myers clears another hurdle in Merck lung cancer showdown — but big challenges remain [EndPoints] The study is still ongoing, with researchers looking to nail down the overall survival rate. The company based their sNDA on data demonstrating that the one-year progression-free survival rate was 42.6% with the Opdivo plus Yervoy combination versus 13.2% with chemotherapy for patients in the target TMB group.
	5.12.6 Immunothérapies - AMM
FDA slaps new bladder cancer limits on Merck's Keytruda, Roche's Tecentriq [FiercePharma] The changes mark a setback for both Merck and Roche in an ultracompetitive area.
	5.2 Pharma
Nanobiotix soars as late-phase cancer trial hits endpoint [FierceBiotech] The tight squeeze under the 0.05 bar of statistical significance leaves scope for skeptical readings of the data, as do other aspects of the top-line information shared—and not shared—by Nanobiotix.
	5.3 Traitements - FDA, EMA, NICE...
Prasad: FDA has confused merely approving drugs with making the world a better place [The cancer Letter] The time had come to give Prasad a call. I had general questions about his thoughts about Twitter, about his views on the FDA standards for drug approval, and—more urgently—I had profound questions about statistical and methodological underpinnings of the two opinion pieces cited in the Times editorial.
Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine [The Cancer Letter] I have been tracking Prasad’s pronouncements for a few years, and—like everyone I know—I agreed with some of what I read, and never looked deeply at his argumentation. The Times editorial changed that. Prasad’s recommendations were being proposed as a basis for approval of cancer drugs.
	5.4 Traitements - Economie
A Drug Costs $272,000 a Year. Not So Fast, Says New York State. [NY Times] New York’s Medicaid program says Orkambi, a new drug to treat cystic fibrosis, is not worth the price. The case is being closely watched around the country.
	5.5.16 ASCO (médecine de précision)
Tweeting Oncologist Draws Ire And Admiration For Calling Out Hype [NPR] Dr. Richard Schilsky, ASCO's chief medical officer, moderated the conversation and came away in considerable agreement with Prasad. "I enjoy his remarks very much," he says afterward. "I mean, he's a bit of a gadfly. He's a bit of a provocateur. But frankly, he's taking a very hard and objective look at a very complex area and ... he's saying what's behind the curtain.
	6.10.1 Politiques (USA)
A slimmer FDA: White House proposes 30% cut to headcount under reorganization [EndPoints] What’s certain is that Scott Gottlieb, the nation’s 23rd Commissioner of Food and Drugs, has taken an especially personal interest in his role as guardian of the food supply with regular tweets and communiques to the public on matters from proper cooking techniques and recall notices, and he isn’t likely to give up that responsibility so fast.
	6.7.1 IA/bioinformatique
Dana-Farber Releases Source Code for MatchMiner Cancer Trial Matcher [Genome Web] MatchMiner automates the process of pairing candidates with clinical trials and vice-versa, for the benefit of clinicians, trial investigators, and cancer patients alike.